Licensing of Contrast Agents in Europe ▼
UCA registered in Europe are licensed only for cardiac or, in the case of SonoVue ® , for liver and vascular applications. SonoVue is used with ultrasound imaging to enhan ce the echogenicity of the blood, by impro ving signal to noise ratio; increase the ac curacy in detection or exclusion of abnor malities in cerebral arteries and extracra nial carotid or peripheral arteries by im proving the Doppler signal to noise ratio (Doppler of macrovasculature); and incre ase the quality of the Doppler flow image and the duration of clinicallyuseful signal enhancement in portal vein assessment. SonoVue ® also improves imaging of liver and breast lesion vascularity during Doppler sonography, leading to more spe cific lesion characterisation (Doppler of microvasculature) [5] . In addition to li censed indications with a focus on the liver and Doppler enhancement, SonoVue is safe [6] and effective [7] for examination of almost all organs, as recently published by European guidelines [4] . These publis hed clinical recommendations on the use of CEUS are based on comprehensive lite rature surveys, including results from pro spective clinical trials, and incorporate many indications currently off-label. The current legal requirements for the re gistration of pharmaceutical products in Europe are strict. In order for a new indi cation to be registered, the manufacturer must provide data on safety and efficacy, with a dedicated phase III trial specifically designed to achieve that registration ap proval. Diagnostic agents, including cont rast microbubbles, are no exception to this rule, which is designed to protect patients from the misuse of drugs or diagnostic agents but may limit the potential benefit to patients. Applications for novel indications not only follow clinical or scientific needs, but also the financial expectations of the producer and health care funding entities. For some products, the marketing forecast of in come from the additional indications is lo wer than the costs of a registration trial, so that new indications are unlikely to ap pear. In these cases, lack of registration does not equal lack of efficacy of a marke ted compound used for an off-label indi cation. Patients could be individually in formed to consider consenting to nonli censed investigations, which would be up to the discretion of the physician.
Off-label Use in Children ▼
Off-label use is of utmost importance in pediatrics because many drugs are not tested by randomized trials in children, which also means that they are not speci fically licensed for use in children [8] . Li censed drugs are often prescribed outside the terms of the product license in relation to age. Over two thirds (67 %) of 624 child ren admitted to wards in five European hospitals received drugs prescribed in an unlicensed or off-label manner and 39 % of the 2262 drug prescriptions given to children were off-label [9] . Licensed drugs
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for adults may only be used in children af ter the parents (or legal representatives) have been adequately informed, and spe cific consent has been obtained, with an exception for emergency cases. Diag nostic agents, including contrast micro bubbles, are no exception to this rule [4] . Thus, before SonoVue ® or any other agent can be used routinely in children, a dedi cated trial which demonstrates efficacy and safety has to be performed. Until this happens the agent will remain off-label for pediatric use. Unfortunately, these ru les, which are designed to protect pati ents, occasionally, limits the potential be nefit to patients, if, for instance, a sonogra pher refuses to perform off-label indica tions. There is one currently licensed indication for UCA in pediatrics; Levovist ® (Bayer, Germany) is registered for vesicoureteric studies. However, Levovist ® has a limited market and its production has been dis continued [4] , leaving an important diag nostic need unmet. In many clinics, this void is presently filled by the non-licensed SonoVue ® . This is just one example sup porting the off-label use of UCA in child ren due to diagnostic benefits such as high efficacy and great overall safety. For a more in depth examination of this subject I refer the reader to the recently published EFSUMB comments [10] on a recently published paper [11] and additi onal current literature [12] .
Off-label Use and Funding ▼
In general, drugs that are neither not li censed for the pharmaceutical market, nor for a respective indication may not be prescribed by any physician except under clinical trial conditions or individual clini cal advice. Sickness funds may not fund clinical research, cover prescriptions of unlicensed drugs, or cover unlicensed in dications. In many countries only a time consuming, individual clarification pro cess with the sickness fund may offer a so lution [8;13-16] .
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